Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H20ClN3O2.ClH |
Molecular Weight | 346.252 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC(N)=C(Cl)C=C1C(=O)NC2CN3CCC2CC3
InChI
InChIKey=ITXVOUSORXSTQH-UHFFFAOYSA-N
InChI=1S/C15H20ClN3O2.ClH/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19;/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20);1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20950056Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1514881 | https://www.ncbi.nlm.nih.gov/pubmed/12540230 | https://www.ncbi.nlm.nih.gov/pubmed/24365159 | https://www.ncbi.nlm.nih.gov/pubmed/1312602 | https://www.ncbi.nlm.nih.gov/pubmed/8263156
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20950056
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1514881 | https://www.ncbi.nlm.nih.gov/pubmed/12540230 | https://www.ncbi.nlm.nih.gov/pubmed/24365159 | https://www.ncbi.nlm.nih.gov/pubmed/1312602 | https://www.ncbi.nlm.nih.gov/pubmed/8263156
Zacopride is a potent antagonist at the 5-HT3 receptor and an agonist at the 5-HT4 receptor with antiemetic, anxiolytic and nootropic effects in animal models. Zacopride also has pro-respiratory effects, both reducing sleep apnea and reversing opioid-induced respiratory depression in animal studies. Zacopride has been tested in clinical trials for the treatment of schizophrenia but was found unsuccessful.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1899 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24365159 |
0.39 nM [Ki] | ||
Target ID: CHEMBL2094132 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1312602 |
1.5 nM [Ki] | ||
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12540230 |
5.95 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus. | 1995 Oct 27 |
|
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor. | 1996 May 23 |
|
Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor. | 1996 Nov 25 |
|
[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. | 1997 Apr-May |
|
Cloning and expression of human 5-HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase. | 1997 Oct 20 |
|
Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4 receptor isoforms produced by alternative splicing in the carboxyl terminus. | 1998 Jun |
|
Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT(3) receptor antagonist, in the mouse elevated plus-maze. | 2001 Jul-Aug |
|
Different receptor subtypes are involved in the serotonin-induced modulation of epileptiform activity in rat frontal cortex in vitro. | 2001 Jun |
|
Imipramine but not 5-HT(1A) receptor agonists or neuroleptics induces adaptive changes in hippocampal 5-HT(1A) and 5-HT(4) receptors. | 2002 May 17 |
|
MD-354 potentiates the antinociceptive effect of clonidine in the mouse tail-flick but not hot-plate assay. | 2004 Jul 14 |
|
5-HT(3) receptors, alcohol and aggressive behavior in mice. | 2005 May |
|
Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. | 2006 May |
|
Imipramine and citalopram reverse corticosterone-induced alterations in the effects of the activation of 5-HT(1A) and 5-HT(2) receptors in rat frontal cortex. | 2006 Sep |
|
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials. | 2009 Jun |
|
5-HT inhibition of rat insulin 2 promoter Cre recombinase transgene and proopiomelanocortin neuron excitability in the mouse arcuate nucleus. | 2009 Mar 3 |
|
Investigations into the binding affinities of different human 5-HT4 receptor splice variants. | 2010 |
|
Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1514881
0.2, 0.4, 0.8 and 1.6 mg/day for 4 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8263156
Adrenal explants, obtained from patients undergoing expanded nephrectomy for kidney cancer, were immediately transported to the laboratory in Dulbecco Modified Eagle’s Medium (DMBM). After dissection and preincubation in DMEM at 20 C, adrenocortical fragments consisting of both glomerulosa and fasciculata zones were mixed with Bio-Gel P2 and transferred into perifusion chambers. Each perifusion column contained approximately 100 mg wet tissue: The perifusion chambers were supplied with DMEM at a constant flow rate (260 mkL/min). The pH (7.4) and temperature (37 C) were kept constant throughout the experiment. The perifusion medium was continuously gassed with a 95% O2-5% CO2 mixture. The tissues were allowed to stabilize for 2 h before zacopride was administered. Zacopride was dissolved in gassed DMEM and infused for 20 min into the perifusion chambers at the same flow rate as DMEM alone by means of a multichannel peristaltic pump. Fractions of the effluent perifusate were collected every 5 min and immediately frozen until assay. Aldosterone and cortisol concentrations were determined by RIA.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BJ3775635U
Created by
admin on Sat Dec 16 04:40:27 GMT 2023 , Edited by admin on Sat Dec 16 04:40:27 GMT 2023
|
PRIMARY | |||
|
101303-98-4
Created by
admin on Sat Dec 16 04:40:27 GMT 2023 , Edited by admin on Sat Dec 16 04:40:27 GMT 2023
|
PRIMARY | |||
|
9928181
Created by
admin on Sat Dec 16 04:40:27 GMT 2023 , Edited by admin on Sat Dec 16 04:40:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD